SCHEMBL4744729

SCHEMBL4744729

Cl[Ru](Cl)=C1C=C(c2ccccc2)c2ccccc21.c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PTPN1 P18031 2/20 0.40
PTPRC P08575 2/20 0.40
PTPRF P10586 1/20 0.40
CDC25B P30305 1/20 0.40
ESR1 P03372 2/20 0.33
ESR2 Q92731 2/20 0.33
BACE1 P56817 2/20 0.33
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
CYP2A6 P11509 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29555282 0.89 PTPN1 (0.47) PTPN1PTPRCPTPRFCDC25BBACE1
SCHEMBL28887375 0.76 PTPN1 (0.34) PTPN1PTPRCPTPRFCDC25BALDH1A1
SCHEMBL17047977 0.74 CYP3A4 (0.38) CYP3A4TDP1PTPN1PTPRCPTPRF
SCHEMBL29860849 0.74 PTPN1 (0.35) PTPN1PTPRCPTPRFCDC25BBACE1
Hydrochloric Acid SCHEMBL4804358 0.72 CYP3A4 (0.43) CYP3A4TDP1PTPN1PTPRCPTPRF
SCHEMBL4215127 0.69 CYP3A4 (0.52) CYP3A4TDP1ESR1ESR2
SCHEMBL6886030 0.69 CYP3A4 (0.75) CYP3A4TDP1ESR1ESR2ALDH1A1
SCHEMBL1258556 0.69 CYP3A4 (0.75) CYP3A4TDP1ESR1ESR2ALDH1A1
SCHEMBL28390312 0.69 CYP3A4 (0.75) CYP3A4TDP1ESR1ESR2ALDH1A1
SCHEMBL31539924 0.66 CYP3A4 (0.71) CYP3A4TDP1ESR1ESR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2864341-B1 METHOD FOR PREPARATION OF A RUTHENIUM INDENYLIDENE COMPLEX UMICORE AG & CO KG (DE) 2018-09-26 EP disclosed
EP-2679593-B1 Method for preparation of a ruthenium indenylidene complex UMICORE AG & CO KG (DE) 2018-03-21 EP disclosed
US-9604205-B2 Method for preparation of a ruthenium indenylidene complex UMICORE AG & CO. KG (DE) 2017-03-28 US disclosed
US-20170043332-A1 Method for Preparation of a Ruthenium Indenylidene Complex UMICORE AG & CO KG (DE) 2017-02-16 US disclosed
US-20160228864-A1 Method for Preparation of a Ruthenium Indenylidene Complex UMICORE AG & CO KG (DE) 2016-08-11 US disclosed
US-9339804-B2 Method for preparation of a ruthenium indenylidene complex UMICORE AG & CO. KG (DE) 2016-05-17 US disclosed
US-20150190795-A1 Method for Preparation of a Ruthenium Indenylidene Complex UMICORE AG & CO. KG (DE) 2015-07-09 US disclosed
WO-2008102157-A1 CATALYTIC METHOD THE UNIVERSITY OF BRISTOL (GB) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150190795-A1 Method for Preparation of a Ruthenium Indenylidene Complex RPL3, RPL13A, PRPF3 CYP3A4 694/4885TDP1 2605/4885PTPN1 4247/4885
US-20160228864-A1 Method for Preparation of a Ruthenium Indenylidene Complex RPL3, RPL13A, UPP1 CYP3A4 684/4885TDP1 2613/4885PTPN1 4237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.